We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus.
Annals of the Rheumatic Diseases 2020 March
OBJECTIVES: To investigate associations between a high genetic disease risk and disease severity in patients with systemic lupus erythematosus (SLE).
METHODS: Patients with SLE (n=1001, discovery cohort and n=5524, replication cohort) and healthy controls (n=2802 and n=9859) were genotyped using a 200K Immunochip single nucleotide polymorphism array. A genetic risk score (GRS) was assigned to each individual based on 57 SLE risk loci.
RESULTS: SLE was more prevalent in the high, compared with the low, GRS-quartile (OR 12.32 (9.53 to 15.71), p=7.9×10-86 and OR 7.48 (6.73 to 8.32), p=2.2×10-304 for the discovery and the replication cohorts, respectively). In the discovery cohort, patients in the high GRS-quartile had a 6-year earlier mean disease onset (HR 1.47 (1.22 to 1.75), p=4.3×10-5 ), displayed higher prevalence of damage accrual (OR 1.47 (1.06 to 2.04), p=2.0×10-2 ), renal disorder (OR 2.22 (1.50 to 3.27), p=5.9×10-5 ), anti-dsDNA (OR 1.83 (1.19 to 2.81), p=6.1×10-3 ), end-stage renal disease (ESRD) (OR 5.58 (1.50 to 20.79), p=1.0×10-2 ), proliferative nephritis (OR 2.42 (1.30 to 4.49), p=5.1×10-3 ), anti-cardiolipin-IgG (OR 1.89 (1.13 to 3.18), p=1.6×10-2 ), anti-β2 -glycoprotein-I-IgG (OR 2.29 (1.29 to 4.06), p=4.8×10-3 ) and positive lupus anticoagulant test (OR 2.12 (1.16 to 3.89), p=1.5×10-2 ) compared with patients in the low GRS-quartile. Survival analysis showed earlier onset of the first organ damage (HR 1.51 (1.04 to 2.25), p=3.7×10-2 ), first cardiovascular event (HR 1.65 (1.03 to 2.64), p=2.6×10-2 ), nephritis (HR 2.53 (1.72 to 3.71), p=9.6×10-7 ), ESRD (HR 6.78 (1.78 to 26.86), p=6.5×10-3 ) and decreased overall survival (HR 1.83 (1.02 to 3.30), p=4.3×10-2 ) in high to low quartile comparison.
CONCLUSIONS: A high GRS is associated with increased risk of organ damage, renal dysfunction and all-cause mortality. Our results indicate that genetic profiling may be useful for predicting outcomes in patients with SLE.
METHODS: Patients with SLE (n=1001, discovery cohort and n=5524, replication cohort) and healthy controls (n=2802 and n=9859) were genotyped using a 200K Immunochip single nucleotide polymorphism array. A genetic risk score (GRS) was assigned to each individual based on 57 SLE risk loci.
RESULTS: SLE was more prevalent in the high, compared with the low, GRS-quartile (OR 12.32 (9.53 to 15.71), p=7.9×10-86 and OR 7.48 (6.73 to 8.32), p=2.2×10-304 for the discovery and the replication cohorts, respectively). In the discovery cohort, patients in the high GRS-quartile had a 6-year earlier mean disease onset (HR 1.47 (1.22 to 1.75), p=4.3×10-5 ), displayed higher prevalence of damage accrual (OR 1.47 (1.06 to 2.04), p=2.0×10-2 ), renal disorder (OR 2.22 (1.50 to 3.27), p=5.9×10-5 ), anti-dsDNA (OR 1.83 (1.19 to 2.81), p=6.1×10-3 ), end-stage renal disease (ESRD) (OR 5.58 (1.50 to 20.79), p=1.0×10-2 ), proliferative nephritis (OR 2.42 (1.30 to 4.49), p=5.1×10-3 ), anti-cardiolipin-IgG (OR 1.89 (1.13 to 3.18), p=1.6×10-2 ), anti-β2 -glycoprotein-I-IgG (OR 2.29 (1.29 to 4.06), p=4.8×10-3 ) and positive lupus anticoagulant test (OR 2.12 (1.16 to 3.89), p=1.5×10-2 ) compared with patients in the low GRS-quartile. Survival analysis showed earlier onset of the first organ damage (HR 1.51 (1.04 to 2.25), p=3.7×10-2 ), first cardiovascular event (HR 1.65 (1.03 to 2.64), p=2.6×10-2 ), nephritis (HR 2.53 (1.72 to 3.71), p=9.6×10-7 ), ESRD (HR 6.78 (1.78 to 26.86), p=6.5×10-3 ) and decreased overall survival (HR 1.83 (1.02 to 3.30), p=4.3×10-2 ) in high to low quartile comparison.
CONCLUSIONS: A high GRS is associated with increased risk of organ damage, renal dysfunction and all-cause mortality. Our results indicate that genetic profiling may be useful for predicting outcomes in patients with SLE.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app